Contract analysis

I. EXECUTIVE SUMMARY This memorandum presents the results of our regulatory due diligence assessment of Meridian Surgical Technologies, Inc. ("Meridian" or "MST"), a Delaware corporation headquartered at 780 Keystone Boulevard, Suite 200, King of Prussia, Pennsylvania 19406, with its principal manufacturing facility located at 45 Forge Creek Road, Exton, Pennsylvania 19341. This assessment has been conducted in conne

II. MERIDIAN'S PRINCIPAL BUSINESS AND PRODUCT PORTFOLIO Meridian Surgical Technologies, Inc. is a medical device company that designs, develops, and manufactures minimally invasive surgical instruments and systems for orthopedic procedures, with a particular focus on arthroscopic surgery. Founded in 2009, Meridian has established itself as a recognized player in the arthroscopic instrumentation market, serving hospit

III. EXISTING FDA 510(k) CLEARANCES — COMMERCIAL PRODUCTS A. Overview of Meridian's 510(k) Clearance History Meridian holds current, valid FDA 510(k) clearances for all of its commercially marketed products. We have confirmed each clearance through a review of the FDA's publicly available 510(k) Premarket Notification database and cross-referenced each clearance against the internal 510(k) submission packages and FDA

IV. FDA INSPECTION HISTORY AND COMPLIANCE STATUS A. Inspection History The most recent FDA inspection of Meridian's Exton, Pennsylvania manufacturing facility was conducted in September 2023. The inspection was a routine Quality System Regulation ("QSR") surveillance inspection conducted under 21 CFR Part 820. We have reviewed the FDA inspection classification database, which confirms that the September 2023 inspecti

V. QUALITY MANAGEMENT SYSTEM AND ISO 13485:2016 CERTIFICATION A. ISO 13485:2016 Certification Meridian's Exton, Pennsylvania manufacturing facility holds ISO 13485:2016 certification, the internationally recognized quality management system standard for medical device manufacturers. ISO 13485:2016 specifies requirements for a quality management system in which an organization needs to demonstrate its ability to provi

VI. ARTHRONAV ROBOTIC-ASSISTED ARTHROSCOPY PLATFORM — REGULATORY PATHWAY ANALYSIS A. Product Description The ArthroNav platform is a robotic-assisted arthroscopic navigation system designed to enhance the precision, consistency, and clinical outcomes of minimally invasive orthopedic arthroscopy procedures. The platform integrates robotic-assisted instrument guidance with advanced software-based surgical navigation ca

1. Pathway Agreement. FDA generally agreed that the 510(k) premarket notification pathway is appropriate for the ArthroNav Generation 1.0 robotic-assisted arthroscopy system, given the availability of a cleared predicate device and the similarity of intended use and technological characteristics.

2. Predicate Device Confirmation. FDA confirmed that predicate device K203847 (Marlowe Asset Management Robotic Surgical Assist System) is an acceptable predicate for the ArthroNav Generation 1.0 submission. FDA did not identify any concerns with the predicate device selection or the proposed substantial equivalence comparison.

3. Recommended Performance Testing. FDA provided feedback on recommended performance testing protocols for the 510(k) submission, including: (a) Bench testing for accuracy and repeatability of the robotic navigation system, including end-effector positioning accuracy, path tracking fidelity, and repeatability under simulated surgical conditions; (b) Software validation in accordance with IEC 62304 (Medical device sof

4. Clinical Data. FDA indicated that clinical data would likely not be required for the Generation 1.0 510(k) submission, provided that the bench testing adequately demonstrates substantial equivalence to the predicate device. However, FDA expressly reserved the right to request clinical data during the formal review process if the submitted bench data does not satisfactorily address all questions of substantial equi

5. Generation 2.0 Software Module. FDA's feedback on the Generation 2.0 ArthroNav Software Module for Real-Time Cartilage Mapping was less definitive. FDA indicated that the appropriate submission pathway for the Generation 2.0 module — whether it could be submitted as a supplement to the Generation 1.0 510(k), or whether it would require a separate, standalone 510(k) submission — would depend on whether the cartilag

1. Development Delays. If bench testing, software validation, biocompatibility testing, or electrical safety testing encounters unexpected difficulties or yields unfavorable results requiring design modifications and re-testing, the 510(k) submission date could be pushed beyond Q2 2025. Software validation, in particular, is a complex and time-intensive process that is susceptible to scope expansion and unforeseen is

2. FDA Request for Clinical Data. Although FDA indicated during the Q-Sub meeting that clinical data would likely not be required for the Generation 1.0 submission, FDA expressly reserved the right to request clinical data during formal review. If FDA determines that the bench testing data does not adequately demonstrate substantial equivalence and requests clinical data, this would significantly delay the timeline —

3. Change in FDA Posture. Q-Sub feedback is non-binding, and FDA's review posture can be influenced by changes in reviewer assignment, division leadership, policy guidance documents, or broader agency priorities. A change in FDA's position on the appropriateness of the 510(k) pathway, the acceptability of the predicate device, or the adequacy of the proposed testing protocols could introduce significant uncertainty a

4. Predicate Device Issues. If the identified predicate device (K203847, Marlowe Asset Management Robotic Surgical Assist System) becomes the subject of any post-market action — such as a recall, safety alert, reclassification proceeding, or withdrawal of clearance — it could undermine the substantial equivalence argument and require Meridian to identify an alternative predicate or restructure its submission strategy

5. Key Personnel Dependency. The ArthroNav development program is heavily dependent on Dr. Raj Subramanian, who serves as CTO and as the principal inventor and technical lead. Loss of Dr. Subramanian's involvement — whether due to departure, reassignment, or other factors — would materially impact the development timeline and the quality of the 510(k) submission. The SPA is expected to include a covenant restricting

1. Technical Maturity. The cartilage mapping algorithms are still under active development. There is inherent uncertainty regarding whether the algorithms will perform with sufficient accuracy and reliability to support a 510(k) submission within the contemplated timeline.

2. Potential Need for Clinical Data. If FDA views the real-time cartilage mapping software as introducing a new intended use — for example, as a diagnostic tool for assessing cartilage condition rather than merely a navigation aid — FDA may require clinical data to support the 510(k) submission. This would likely make the June 30, 2027 deadline unachievable.

3. Short Window Between Milestones. As noted above, the six-month window between the Milestone 1 and Milestone 2 deadlines provides very little margin for delays or complications.

4. Dependence on Generation 1.0 Clearance. The Generation 2.0 submission strategy is predicated on leveraging the Generation 1.0 clearance as a foundation. If Generation 1.0 clearance is delayed, the cascading impact on the Generation 2.0 timeline could be significant. Overall Probability Assessment. We assess the likelihood of achieving Milestone 2 within the June 30, 2027 deadline as moderate, with a meaningful ris

1. Commercially Reasonable Efforts. The Buyer will be required to use "commercially reasonable efforts" to pursue the 510(k) submissions for both the Generation 1.0 and Generation 2.0 ArthroNav products during the Earnout Period. The definition of "commercially reasonable efforts" in the earnout context is a critical negotiation point. The Sellers will likely seek a definition that imposes affirmative obligations on

2. Minimum R&D Budget. The Buyer must maintain a dedicated research and development budget of no less than $6,000,000 per year for the ArthroNav program during the Earnout Period. This covenant provides a quantifiable floor on the Buyer's investment in the ArthroNav program and serves as an objective benchmark for compliance.

3. Key Personnel Protection. The Buyer may not divert Dr. Raj Subramanian from ArthroNav development activities without the prior consent of the Sellers' Representative (Dr. Marcus Ellsworth). This covenant is designed to protect against the risk that the Buyer would reassign Dr. Subramanian to other projects, thereby undermining the ArthroNav development timeline.

4. Non-Abandonment. The Buyer may not discontinue or abandon the ArthroNav program without providing 90 days' prior written notice to the Sellers' Representative. This covenant provides the Sellers' Representative with advance notice of any decision to discontinue the program and an opportunity to engage in dialogue with the Buyer before such a decision is implemented.

5. Dispute Resolution. Disputes regarding earnout achievement are to be resolved by binding expert determination conducted by an independent regulatory consultant mutually selected by the parties. If the parties are unable to agree on the selection of the independent regulatory consultant within 30 days, the consultant will be appointed by the American Arbitration Association. This dispute resolution mechanism is des

VII. PENDING INTELLECTUAL PROPERTY LITIGATION — IMPACT ON REGULATORY POSTURE One pending patent infringement matter is relevant to the Transaction. In Hartwell Orthopedic Solutions, Inc. v. Meridian Surgical Technologies, Inc., Civil Action No. 2:23-cv-04817, filed in the United States District Court for the Eastern District of Pennsylvania, the plaintiff Hartwell Orthopedic Solutions, Inc. ("Hartwell") alleges that

VIII. REGULATORY RISKS AND RECOMMENDATIONS A. Summary of Key Regulatory Risks Based on the regulatory due diligence review described in this memorandum, we have identified the following key regulatory risks that should be considered in connection with the Transaction:

1. ArthroNav Timeline Risk. Delays in bench testing, software validation, biocompatibility testing, electrical safety testing, or 510(k) submission preparation could push the ArthroNav submission and clearance dates beyond the earnout milestone deadlines. This risk is particularly acute for Milestone 2 (Generation 2.0 software module, due June 30, 2027), which has a tighter timeline and is in an earlier stage of deve

2. FDA Position Changes. Q-Sub feedback is non-binding, and FDA retains discretion to take a different position during the formal 510(